X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs CADILA HEALTHCARE - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA CADILA HEALTHCARE TORRENT PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 45.1 18.6 242.5% View Chart
P/BV x 6.1 4.2 145.4% View Chart
Dividend Yield % 0.8 1.0 86.1%  

Financials

 TORRENT PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
CADILA HEALTHCARE
Mar-18
TORRENT PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,550558 277.8%   
Low Rs1,144362 316.3%   
Sales per share (Unadj.) Rs354.7116.3 305.0%  
Earnings per share (Unadj.) Rs40.117.9 224.3%  
Cash flow per share (Unadj.) Rs64.223.1 277.6%  
Dividends per share (Unadj.) Rs14.003.50 400.0%  
Dividend yield (eoy) %1.00.8 136.6%  
Book value per share (Unadj.) Rs273.185.4 319.8%  
Shares outstanding (eoy) m169.221,023.74 16.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.84.0 96.0%   
Avg P/E ratio x33.625.7 130.6%  
P/CF ratio (eoy) x21.019.9 105.5%  
Price / Book Value ratio x4.95.4 91.6%  
Dividend payout %34.919.6 178.3%   
Avg Mkt Cap Rs m227,897470,664 48.4%   
No. of employees `00014.711.8 124.4%   
Total wages/salary Rs m11,35318,545 61.2%   
Avg. sales/employee Rs Th4,083.010,072.7 40.5%   
Avg. wages/employee Rs Th772.31,569.1 49.2%   
Avg. net profit/employee Rs Th461.31,547.7 29.8%   
INCOME DATA
Net Sales Rs m60,021119,049 50.4%  
Other income Rs m2,9881,132 264.0%   
Total revenues Rs m63,009120,181 52.4%   
Gross profit Rs m13,49328,475 47.4%  
Depreciation Rs m4,0865,388 75.8%   
Interest Rs m3,085911 338.6%   
Profit before tax Rs m9,31023,308 39.9%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5295,644 44.8%   
Profit after tax Rs m6,78118,292 37.1%  
Gross profit margin %22.523.9 94.0%  
Effective tax rate %27.224.2 112.2%   
Net profit margin %11.315.4 73.5%  
BALANCE SHEET DATA
Current assets Rs m52,62382,005 64.2%   
Current liabilities Rs m52,02260,720 85.7%   
Net working cap to sales %1.017.9 5.6%  
Current ratio x1.01.4 74.9%  
Inventory Days Days12073 163.5%  
Debtors Days Days7698 77.5%  
Net fixed assets Rs m85,01683,703 101.6%   
Share capital Rs m8461,024 82.6%   
"Free" reserves Rs m45,37686,421 52.5%   
Net worth Rs m46,22287,445 52.9%   
Long term debt Rs m41,11525,551 160.9%   
Total assets Rs m142,432180,653 78.8%  
Interest coverage x4.026.6 15.1%   
Debt to equity ratio x0.90.3 304.4%  
Sales to assets ratio x0.40.7 63.9%   
Return on assets %6.910.6 65.2%  
Return on equity %14.720.9 70.1%  
Return on capital %14.222.0 64.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58042,683 34.2%   
Fx outflow Rs m3,60011,242 32.0%   
Net fx Rs m10,98031,441 34.9%   
CASH FLOW
From Operations Rs m8,9429,193 97.3%  
From Investments Rs m-47,070-9,737 483.4%  
From Financial Activity Rs m34,174515 6,635.7%  
Net Cashflow Rs m-3,655-29 12,603.4%  

Share Holding

Indian Promoters % 71.5 74.8 95.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 8.3 84.6%  
FIIs % 12.6 5.9 213.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 11.0 80.0%  
Shareholders   26,511 44,069 60.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  MERCK LTD  

Compare TORRENT PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Nov 15, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - BIOCON LTD COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS